Review Article

PET and PET/CT with 68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors

Table 3

Summary of the role of positron emission tomography and positron emission tomography/computed tomography with 68Ga-radiolabeled somatostatin analogues in tumors other than gastroenteropancreatic neuroendocrine tumors.

Tumor typeReferencesPublications Patients  68Ga-somatostatin-analogues PET or PET/CT purposeFuture perspective*
Diagnosis/stagingPRRT selectionOther

Sympathoadrenal system tumors
 Paraganglioma[3133, 37, 38, 40, 41, 48, 50, 67]10 xx++
 Phaechromocytoma[3237, 39] 7 xxx++
Lung tumors
 Carcinoid[4050, 66, 67] 13 xx++
 NSCLC[43, 51] 2 xx+/−
 SCLC[43, 47, 52] 3 xx+
Brain tumors
 Neuroepithelial tumor[32, 36, 5355]5 xxx+/−
 Meningioma[53, 5563]9 xx++
Thyroid cancers
 MTC[33, 40, 47, 6467] 7 xx++
 DTC[32, 6870, 80] 5 xx++
Merkel cell carcinoma[48, 67, 7477] 6 xxx+/−
Colorectal cancer[80, 81] 2 x+/−
Breast cancer[78] 12 x+/−
Prostate cancer[31, 41, 48, 49, 8385] 7 x+/−
Melanoma [48, 82] 2 x+/−
Thymic cancer[40, 48, 66, 67, 7173]8 xx
Mesenchymal tumor[32, 39, 8688] 5 x+
Lymphoma[31, 80]2 x

PET: positron emission tomography; PET/CT: positron emission tomography/computed tomography; PRRT: peptide radioreceptor therapy; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MTC: medullary thyroid cancer; DTC: differentiated thyroid cancer. Based on literature data we classified the use of radiolabeled somatostatin-analogues PET or PET/CT as ++: suitable; +: promising; +/−: undetermined; and −: not indicated.